Sponsor:Merck Sharp & Dohme, a subsidiary of Merck
Funder:Merck Sharp & Dohme
TECOS evaluated the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.
Randomised, placebo-controlled global clinical trial performed in 14,735 patients who were enrolled between 2009 and 2012. TECOS was coordinated jointly by the DTU and the Duke Clinical Research Institute (DCRI) and conducted in 38 countries.
The results of TECOS were reported at the 2015 meeting of the ADA. It met its primary safety endpoint of non-inferiority for the primary composite cardiovascular endpoint of (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for unstable angina). Rates of hospitalization for heart failure, acute pancreatitis and pancreatic cancer did not differ between the two groups. The primary results paper is available here.
A slide set displaying the primary results of TECOS, as presented at the ADA on Mon 8th June 2015, is freely-available for download via the link below.
The TECOS study group presented the primary results today to an audience of over 6,500 attendees at the 75th Annual Scientific Sessions of the American Diabetes Society in Boston, Massachusetts, US.